JP2014513956A5 - - Google Patents

Download PDF

Info

Publication number
JP2014513956A5
JP2014513956A5 JP2014508520A JP2014508520A JP2014513956A5 JP 2014513956 A5 JP2014513956 A5 JP 2014513956A5 JP 2014508520 A JP2014508520 A JP 2014508520A JP 2014508520 A JP2014508520 A JP 2014508520A JP 2014513956 A5 JP2014513956 A5 JP 2014513956A5
Authority
JP
Japan
Prior art keywords
peptide
acid sequence
amino acid
seq
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014508520A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014513956A (ja
JP6407714B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/035026 external-priority patent/WO2012149038A1/en
Publication of JP2014513956A publication Critical patent/JP2014513956A/ja
Publication of JP2014513956A5 publication Critical patent/JP2014513956A5/ja
Application granted granted Critical
Publication of JP6407714B2 publication Critical patent/JP6407714B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014508520A 2011-04-25 2012-04-25 短縮型ｈｉｖエンベロープタンパク質（ｅｎｖ）、前記に関連する方法及び組成物 Expired - Fee Related JP6407714B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161478857P 2011-04-25 2011-04-25
US61/478,857 2011-04-25
PCT/US2012/035026 WO2012149038A1 (en) 2011-04-25 2012-04-25 Truncated hiv envelope proteins (env), methods and compositions related thereto

Publications (3)

Publication Number Publication Date
JP2014513956A JP2014513956A (ja) 2014-06-19
JP2014513956A5 true JP2014513956A5 (enExample) 2015-06-18
JP6407714B2 JP6407714B2 (ja) 2018-10-17

Family

ID=46147686

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014508520A Expired - Fee Related JP6407714B2 (ja) 2011-04-25 2012-04-25 短縮型ｈｉｖエンベロープタンパク質（ｅｎｖ）、前記に関連する方法及び組成物

Country Status (10)

Country Link
US (1) US10081658B2 (enExample)
EP (1) EP2701736A1 (enExample)
JP (1) JP6407714B2 (enExample)
KR (1) KR102007444B1 (enExample)
CN (1) CN103945864A (enExample)
AP (1) AP2013007180A0 (enExample)
CA (1) CA2834288A1 (enExample)
HK (1) HK1200329A1 (enExample)
WO (1) WO2012149038A1 (enExample)
ZA (1) ZA201307529B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32306A (es) 2008-12-09 2010-07-30 Gilead Sciences Inc Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos
EP2981545A4 (en) * 2013-04-02 2016-11-16 Univ Duke RECOMBINANT PREPARATION OF HIV-1 SLEEVE GLYCOPROTEINS
SI3166607T1 (sl) * 2014-07-11 2023-01-31 Gilead Sciences, Inc. Modulatorji toličnih receptorjev za zdravljenje HIV-a
CN110305133A (zh) 2014-09-16 2019-10-08 吉利德科学公司 Toll样受体调节剂的固体形式
PL3390430T3 (pl) * 2015-12-15 2020-03-31 Janssen Vaccines & Prevention B.V. Antygeny ludzkiego wirusa niedoboru odporności, wektory, kompozycje i sposoby ich zastosowania
US10696985B1 (en) * 2016-06-06 2020-06-30 Vanderbilt University Reversibly crosslinked endosomolytic polymer vesicles for cytosolic drug delivery
CN113924114A (zh) 2019-05-22 2022-01-11 吉利德科学公司 Tlr7调节化合物和hiv疫苗的组合
CN119391775A (zh) * 2019-11-04 2025-02-07 分贝治疗公司 前庭支持细胞启动子和其用途
WO2021226336A1 (en) * 2020-05-06 2021-11-11 The Regents Of The University Of Michigan Compositions and methods for membrane protein structure determination
CN115838408B (zh) * 2022-12-09 2024-11-29 中国农业大学 一种钙调素结合蛋白MxIQM3及其编码基因与应用
CN118515733B (zh) * 2023-02-20 2025-11-18 菲鹏生物股份有限公司 Hiv蛋白及其在检测hiv抗体中的应用

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4769331A (en) 1981-09-16 1988-09-06 University Patents, Inc. Recombinant methods and materials
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
IL84154A0 (en) 1986-10-16 1988-03-31 Microgenesys Inc Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
IL86724A (en) 1987-06-19 1995-01-24 Siska Diagnostics Inc Methods and kits for amplification and testing of nucleic acid sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
EP0359789B1 (en) 1988-01-21 1993-08-04 Genentech, Inc. Amplification and detection of nucleic acid sequences
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
US5130238A (en) 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
WO1990001543A1 (fr) 1988-07-29 1990-02-22 Intracel Corporation Procede d'expression genetique de proteines heterologues par des cellules transfectees in vivo
CA2003300A1 (en) 1988-11-21 1990-05-21 Franklin Volvovitz Skin test and test kit for aids
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5591439A (en) 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
US5552143A (en) 1989-03-24 1996-09-03 The Wistar Institute Of Anatomy & Biology Recombinant cytomegalovirus vaccine
GB9001766D0 (en) 1990-01-25 1990-03-28 Univ Court Of The University O Vaccines
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5514375A (en) 1990-08-15 1996-05-07 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
EP0575491B1 (en) 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
US5997878A (en) 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
FR2676071B1 (fr) * 1991-05-02 1994-11-18 Transgene Sa Nouveau variant gp160 non-clivable, soluble, de forme hybride.
US5169766A (en) 1991-06-14 1992-12-08 Life Technologies, Inc. Amplification of nucleic acid molecules
US5668648A (en) 1991-11-26 1997-09-16 Kabushiki Kaisha Toshiba Computer-assisted holographic display apparatus
US5650398A (en) 1992-07-02 1997-07-22 Cambridge Biotech Corporation Drug delivery enhancement via modified saponins
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
WO1995011995A1 (en) 1993-10-26 1995-05-04 Affymax Technologies N.V. Arrays of nucleic acid probes on biological chips
US6485729B1 (en) 1993-09-13 2002-11-26 Protein Sciences Corporation Neuraminidase-supplemented compositions
US5869255A (en) 1994-02-01 1999-02-09 The Regents Of The University Of California Probes labeled with energy transfer couples dyes exemplified with DNA fragment analysis
US5654419A (en) 1994-02-01 1997-08-05 The Regents Of The University Of California Fluorescent labels and their use in separations
US5795716A (en) 1994-10-21 1998-08-18 Chee; Mark S. Computer-aided visualization and analysis system for sequence evaluation
KR20050052548A (ko) 1994-12-24 2005-06-02 캠브리지 유니버시티 테크니칼 서비스 리미티드 자궁내막기능 또는 자궁내막기능과 관련된 기능의 개선방법
FR2728795B1 (fr) 1994-12-30 1997-03-21 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur un virus herpes aviaire
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5728528A (en) 1995-09-20 1998-03-17 The Regents Of The University Of California Universal spacer/energy transfer dyes
FR2741806B1 (fr) 1995-11-30 1998-02-20 Rhone Merieux Vaccin vivant recombinant a base d'herpesvirus felin de type 1, notamment contre la peritonite infectieuse feline
WO1997029212A1 (en) 1996-02-08 1997-08-14 Affymetrix, Inc. Chip-based speciation and phenotypic characterization of microorganisms
FR2750865B1 (fr) 1996-06-27 1998-12-04 Rhone Merieux Vaccin vivant recombinant a base d'herpesvirus canin, notamment contre la maladie de carre, la rage ou le virus parainfluenza de type 2
FR2750866B1 (fr) 1996-06-27 1998-11-27 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
US6090393A (en) 1996-07-03 2000-07-18 Merial Recombinant canine adenoviruses, method for making and uses thereof
FR2751223B1 (fr) 1996-07-19 1998-12-04 Rhone Merieux Formule de vaccin polynucleotidique felin
FR2751227B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
FR2751229B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins
FR2751226B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
FR2751225B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
FR2751228B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Vaccin polynucleotidique bovin pour voie intradermique
FR2751224B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs
US5853992A (en) 1996-10-04 1998-12-29 The Regents Of The University Of California Cyanine dyes with high-absorbance cross section as donor chromophores in energy transfer labels
WO1999032646A1 (en) 1997-12-22 1999-07-01 Oxford Biomedica (Uk) Limited Equine infectious anaemia virus (eiav) based
PT904392E (pt) 1996-10-17 2001-06-29 Oxford Biomedica Ltd Vectores retrovirais
US6231859B1 (en) 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
FR2757061B1 (fr) 1996-12-16 1999-03-26 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
FR2758986B1 (fr) 1997-01-31 1999-04-30 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
US6183752B1 (en) 1997-02-05 2001-02-06 Pasteur Merieux Serums Et Vaccins Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
US6368603B1 (en) 1997-03-05 2002-04-09 Merial Limited Lyme combination compositions and uses
US6004777A (en) 1997-03-12 1999-12-21 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US5990091A (en) 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US20020136722A1 (en) 1997-06-18 2002-09-26 Heath Andrew William Vaccination method
US6348450B1 (en) 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
AU734180B2 (en) 1997-08-29 2001-06-07 Antigenics Llc Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient
FR2781159B1 (fr) 1998-07-06 2000-10-06 Merial Sas Vaccin circovirus et parvovirus porcin
US6391314B1 (en) 1997-10-03 2002-05-21 Merial Porcine circoviruses vaccines diagnostic reagents
US6224882B1 (en) 1997-11-07 2001-05-01 Protein Science Corp. Insect cells or fractions as adjuvant for antigens
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US6103526A (en) 1998-10-08 2000-08-15 Protein Sciences Corporation Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using
US6497883B1 (en) 1999-06-10 2002-12-24 Merial Porcine circovirus recombinant poxvirus vaccine
AU6845201A (en) 2000-06-15 2001-12-24 Us Gov Health & Human Serv A recombinant non-replicating virus expressing GM-CSF and uses thereof to enhance immune responses
AU2002327338A1 (en) * 2001-07-25 2003-02-17 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
CA2459426A1 (en) * 2001-09-06 2003-03-20 Progenics Pharmaceuticals, Inc. Human immunodeficiency virus envelope glycoprotein mutants and uses thereof
ES2320979T3 (es) 2001-09-24 2009-06-01 Imperial Innovations Limited Pyy-36 para la reduccion o prevencion de la obesidad.
KR100981356B1 (ko) * 2006-01-31 2010-09-14 대한민국 신호서열 및 변이된 신호서열로 디자인된 분비증강자에의한 원래 형태의 수용성 재조합 단백질 생산 방법
US20110064760A1 (en) * 2009-08-14 2011-03-17 Cho Michael W Polypeptides comprising epitopes of hiv gp41 and methods of use

Similar Documents

Publication Publication Date Title
Moore et al. Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development
KR101736897B1 (ko) 인플루엔자 항원 수송 벡터 및 구조물
Dimitrov et al. Role of the fusion peptide and membrane-proximal domain in HIV-1 envelope glycoprotein-mediated membrane fusion
Layton et al. Induction of HIV-specific cytotoxic T lymphocytes in vivo with hybrid HIV-1 V3: Ty-virus-like particles.
JP2019527055A5 (enExample)
Vassilieva et al. Enhanced mucosal immune responses to HIV virus-like particles containing a membrane-anchored adjuvant
CN103992396B (zh) 一种潜在的高效重组HIV‑1 CRF07‑BC gp140免疫原的制备方法
Gonelli et al. Immunogenicity of HIV-1-based virus-like particles with increased incorporation and stability of membrane-bound Env
Fontana et al. Mucosal immunization with integrase-defective lentiviral vectors protects against influenza virus challenge in mice
CN103732249A (zh) 含有经修饰腺病毒载体的流感疫苗
Thippeshappa et al. Oral immunization with recombinant vaccinia virus prime and intramuscular protein boost provides protection against intrarectal simian-human immunodeficiency virus challenge in macaques
CN103946385B (zh) 作为对抗hiv-1的疫苗的嵌合非整合型慢病毒基因组
CN102365095B (zh) 分裂gp41
CN104169295B (zh) 突变的慢病毒env蛋白及其用作药物的用途
Khan et al. Tetravalent SARS-CoV-2 S1 subunit protein vaccination elicits robust humoral and cellular immune responses in SIV-infected rhesus macaque controllers
Garulli et al. Exploring mucosal immunization with a recombinant influenza virus carrying an HIV-polyepitope in mice with pre-existing immunity to influenza
Paul et al. Frequent associations between CTL and T-Helper epitopes in HIV-1 genomes and implications for multi-epitope vaccine designs
KR101756202B1 (ko) 신규한 ｇｐ41 항원
Loop et al. Low-temperature enhances production of severe fever with thrombocytopenia syndrome virus virus-like particles
Garulli et al. Induction of Antibodies and T Cell Responses by a Recombinant Influenza Virus Carrying an HIV‐1 TatΔ51–59 Protein in Mice
Khan et al. TGF-β1 in Aplysia: Role in Long-Term Changes in the Excitability of Sensory Neurons and Distribution of TβR-II-Like Immunoreactivity
CN107224578A (zh) Hiv疫苗及其制备方法
US20170107260A1 (en) Mosaic hiv-1 sequences and uses thereof
Leaman et al. Membrane Env liposomes for immunization with HIV spikes
Mediouni et al. HIV-1 infected patients have antibodies recognizing folded Tat